Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 安徽丰原药业股份有限公司是安徽省规模最大的医药企业、安徽医药行业首家上市公司,现已构建了药品研发、生产、销售三位一体的联盟体系:拥有6个生产基地,44条GMP生产线,主要涉及生物药、化学药及中药的研发、生产和销售.丰原药品涵盖解热镇痛感冒类、妇儿类、神经系统、心血管系统、泌尿系统、营养类、抗生素系列7大类药物、300多个品种.可生产大容量注射剂、水针剂、粉针剂、胶囊剂、散剂、片剂、颗粒剂、膜剂、滴眼剂、贴片等10余个剂型和多种原料药.拥有多个国家级一、二类新药品种并具有多项产品及生产技术的自主知识产权,公司先后被中国科学院、科技部、安徽省认定为高新技术企业,并荣获中国"百姓放心药品牌"。 公司主要业务包括医药制造和商业流通。其中医药制造涉及生物药、化学药及中药的研发、生产和销售,主要产品涵盖解热镇痛、妇儿、神经系统、心血管、泌尿系统、营养类、抗生素、原料药等系列产品;商业流通涉及医药配送和药房零售,现已形成高效、全优、多品种的医药供应服务体系。公司注重新药研发,拥有多个国家一、二类新药品种及多项自主知识产权产品,属国家高新技术企业、全国百姓放心药品牌、中国创新力医药企业。 | ||||||||||||||||||||||||
Main Business | 生物药、化学药及中药的研发、生产和销售;医药配送和药房零售。 | ||||||||||||||||||||||||
Legal Representative | 何宏满 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 张军 | ||||||||||||||||||||||||
Solicitors | 安徽承义律师事务所 | ||||||||||||||||||||||||
Auditors | 北京中证天通会计师事务所有限公司 | ||||||||||||||||||||||||
Tel No | 0551-64846153 | ||||||||||||||||||||||||
Fax No | 0551-64846000 | ||||||||||||||||||||||||
Website | www.bbcayy.com | ||||||||||||||||||||||||
xlyyzj@163.com;xlyyzj@sohu.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 20/09/2000 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ 0.480 | ||||||||||||||||||||||||
DPS(RMB)* | ¥ 0.150 | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 5.691 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 2.736B |
![]() |
Only Chinese content is avaliable |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |